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ABSTRACT
Background. Evidence on the management and treatment
of male breast cancer is scant. We report the analysis of a
multicenter Italian series of patients with male breast cancer
treated with eribulin. To our knowledge, this is the first report
on the use or eribulin in this setting.
Patients and Methods. Patients were retrospectively iden-
tified in 19 reference centers. All patients received eribulin
treatment, according to the standard practice of each center.
Data on the identified patients were collected using a
standardized form and were then centrally reviewed by two
experienced oncologists.
Results. A total of 23 patients (median age, 64 years; range,
42–80) were considered. The median age at the time of
diagnosis of breast cancerwas57 years (range, 42–74).HER2
statuswas negative in 14 patients (61%), and 2 patients (9%)
had triple-negative disease. The most common metastatic
sites were the lung (n 5 14; 61%) and bone (n 5 13; 56%).
Eribulin was administered for a median of 6 cycles (range,
3–15). All patients reported at least stable disease; two
complete responses (9%) were documented. Eribulin was
well-tolerated, with only four patients (17%) reporting
grade 3 adverse events and two (9%) with treatment
interruptions because of toxicity. Eight subjects (35%) did
not report any adverse event during treatment. For patients
with a reported fatal event, the median overall survival
from the diagnosis of metastatic disease was 65 months
(range, 22–228).
Conclusion. Although hampered by all the limitations of
any retrospective case series, the results of the present
study suggest, for the first time, the use of eribulin as
therapy for male breast cancer. The Oncologist 2016;
21:1298–1305
Implications for Practice: Evidence on the management and treatment of male breast cancer is eagerly awaited. Although
hamperedbyall the limitationsofany retrospective case series, the resultsof thepresent study suggest, for the first time,theuseof
eribulin as therapy for male breast cancer.
INTRODUCTION
Male breast cancer is a rare solid neoplasm, accounting for
∼1% of all cancers in men. It has been associated with a
70%–80% survival rate at 5 years [1, 2].The incidence of this
neoplasm has been increasing [1, 3]. A number of biological
differences between male and female breast cancer exist.
Furthermore, male breast cancer is usually diagnosed at a
more advanced age and stage than its female counterpart
and presents with more aggressive features [2, 4, 5].
Despite these differences, the current management of
male breast cancer has been determined from what is known
for female breast cancer [2, 4, 6]. Antiestrogen therapy, with
tamoxifen, aromatase inhibitors, and/or fulvestrant, remains
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themainstay of treatment for male breast cancer patients [6,
7]. However, owing to the rarity of the disease, the use of
these molecules has been investigated mostly in retrospec-
tive, small-size, and often monocentric populations [4, 6].
Therefore, new evidence from multicenter cohorts on the
management and therapy of male breast cancer is eagerly
awaited [1, 2].
Eribulin mesylate is a structurally simplified analog of
halichondrin B, a natural product isolated from the marine
sponge Halichondria okadai. This molecule induces mitotic
blockade at the G2-M phase and apoptosis, thus inhibiting
microtubule polymerization without affecting depolymeriza-
tion [8]. The efficacy and safety of eribulin in the treatment
of female breast cancer have been demonstrated in the
pivotal, phase III EMBRACE (Eisai Metastatic Breast Cancer
Study Assessing Physician’s Choice Versus E7389) trial, which
compared eribulin with the treatment of physician’s choice
in locally advanced or metastatic breast cancer patients who
had received at least two previous chemotherapy regimens,
including both anthracyclines and taxanes [9]. Given the
favorable outcomes and the advantage in overall survival
shownwith eribulin, the European Commission issued in 2011
a marketing authorization valid throughout the European
Union for eribulin for patients with metastatic breast cancer,
after anthracycline and taxane treatment. Moreover, other
evidence, collected in a field-practice setting, lend further
support to the use of eribulin for the treatment of female
breast cancer [10–15].
Thus, eribulin might also be worth investigating in the
treatment of metastatic male breast cancer. We report the
analysis of a multicenter, Italian series of patients with male
breast cancer. To our knowledge, this is the first report on the
use or eribulin in this setting.
PATIENTS AND METHODS
The patients for inclusion in the present case series were
retrospectively identified from 19 reference centers for the
treatment of breast cancer located throughout the Italian
territory. All patients were required to be male, to be affected
by metastatic breast cancer, and to have received eribulin
treatment, according to the standard practice of each center
and the clinical judgment of the treating oncologists. No other
limitations in patient selection were applied. All patients
provided written informed consent before inclusion in the
present analysis. Data from the selected patients were col-
lected at each center using a standardized form andwere then
centrally reviewed by two experienced oncologists.
RESULTS
A total of 23 patients (median age, 64 years; range, 42–80)
were identified and considered for the present case series.
Their characteristics and information on the treatment
received and clinical outcomes are listed in Table 1. Figure 1
shows the individual data on progression-free survival and
overall survival.
Overall, the median age at the diagnosis of breast cancer
was 57 years (range, 42–74), and the median age at the
detection of metastasis was 60 years (range, 45–77). Breast
cancerwas gradedas grade3 in 9 patients (39%) and grade2 in
14 (61%). No cases of grade4 diseasewere documented. HER2
status was negative in 14 patients (61%; i.e., with a score of
0by immunohistochemistry), and3patients (13%) had triple-
negative disease. The median Ki-67 value was 23% (range,
10%–50%).Themost commonmetastatic sites were the lung
(n5 14; 61%) and bone (n513; 56%). Only two patients (9%)
did not undergo surgery. The median number of treatment
lines before the initiation of eribulin was 3 (range, 2–11;
Table 2).
Eribulin was administered for a median of 6 cycles (range,
3–15). All the patients reported at least stable disease. In
addition,twocompleteresponses(9%)andninepartial responses
(39%) were documented.
Eribulinwas overallwell tolerated,with only four patients
(17%) reporting grade3adverseevents and twopatients (9%)
interrupting treatment because of toxicity. Eight subjects
(35%) did not report any adverse event during eribulin
therapy.
At the last follow-up point, 12 patients (52%) were still
alive. For patients with a reported fatal event, the median
overall survival from the diagnosis of metastatic disease was
65months (range, 22–228).A full descriptionofsomecasesof
particular interest is reported in the following paragraphs
(the patient numbers correspond to the patient numbers in
Table 1).
Patient 5
A 54-year-oldmanwas referred to the treating institution in
March 2009 for histologically confirmed breast carcinoma.
Staging of the disease was negative for distant metastases,
and patient had undergone total right mastectomy with
surgical axillary lymph nodes. The histologic examination
revealed poorly differentiated ductal carcinoma, pT3pN2
(8 of 20), grade 3; estrogen receptor, 90%; progesterone
receptor, 60%; HER21, 3. In April 2009, he started adjuvant
chemotherapy with 5-fluorouracil, epirubicin, and cyclo-
phosphamide for six cycles, followed by trastuzumab for
1 year and aromatase inhibitors for 5 years. In March
2013, because of the appearance of intense pelvic pain
symptoms, a total body computed tomography (CT) scan
wasperformed,which showedanosteolytic lesionat the left
ischiopubic branch, multiple vertebral lesions, multiple
bilateral pulmonary lesions and liver lesion. In April 2013, he
started chemotherapywithpaclitaxel plus trastuzumabwith
zoledronic acid until October 2013, when chemotherapy
was interrupted because of disease progression with the
appearance of multiple symptomatic brain lesions. The
patient started palliative whole brain radiotherapy and
second-line therapy with vinorelbine plus trastuzumab. In
March 2014, a total body CTscanwas performed to restage
the disease. The CT scan showed disease progression of
known lung and liver lesions. The patient then started
third-line therapy with lapatinib plus capecitabine until
July 2014. The total body CT scan performed in July 2014
showed disease progression of the lung and liver lesions,
with the appearance of new liver and bone lesions. At that
time, the patient had an Eastern Cooperative Oncology
Group performance status of 2 for tumor-related pain.
After a cardiology examination (electrocardiogram and
echocardiogram), which showed good heart function, in
July 2014 the patient started fourth-line therapy with
www.TheOncologist.com ©AlphaMed Press 2016
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eribulin. A radiological partial response, with radiological
reduction of more than 50% in the sum of the diameters of
the target lesions and stability of the other nontarget
lesions, was obtained after only 2 months of treatment. This
clinical and radiological response was maintained at subsequent
disease restaging, performed every 2 months, with clinical
improvement (Eastern Cooperative Oncology Group per-
formance status of 0), pain relief, and the absence of
relevant side effects. Treatment was continued until
February 2015 without dose modifications. Eribulin was
then interrupted because of disease progression and a
decline in the patient’s clinical condition.
Table 1. Summary of patient and disease characteristics and treatment outcomes
Variable
Patient no.
1 2 3 4 5 6 7
Patient
characteristics
Age (yr) 55 58 70 74 54 61 74
Comorbidities None Hypertension Atrial
fibrillation
None None None Cardiomyopathy
Disease
characteristics
Age at
diagnosis
(yr)
52 55 57 68 54 49 64
Site R L L R R L L
TNM T4N3a
(25/31)M1
pT1N2
(5/15) M0
T4N3M0 T1BN2
(4/10)M0
pT3, pN2
(8/20)
pT1c pN1a
(1/19) M0
pT2, pN1,
cM0
Grade G2 G3 G2 G2 G3 G3 G2
HER2 Neg Neg 11 Neg 3 Neg 21
ER (%) 95 Neg 80 20 90 60 85
PgR (%) 95 Neg 70 16 60 90 90
Ki-67 (%) 15 25 25 10 NE 20 26
LVI Yes No NE NE No NE Yes
Surgery M M M No M M Q
Age at
metastasis
(yr)
52 57 65 71 59 56 69
Site Bone Liver,
bone
Lung,
pleura,
lymph
nodes
Lung,
liver,
lymph
nodes
Bone,
lung, liver
Bone Lung, liver
Previous
lines of
treatment
No. of
lines
5 2 5 3 3 8 3
Longest
PFS (mo)
1 8 48 15 6 10 8
Best
response
SD PR PR SD SD PR PR
Eribulin
No. of
cycles
6 6 4 4 10 7 10
Dose
intensity
TBD 1.23 1.23 1.23 2.3 1.23 1.3
PFS 4 6 3 2 7 3 1
Reason for
interruption
No Patient
decision
PD Poor
conditions
PD Toxicity Exitus
Best
response
PR SD SD SD PR PR CR brain
Toxicity None G2
neutropenia,
nausea,
G1 asthenia
None G2 stypsis None G3
neutropenia,
G2 liver
toxicity
G2
nausea,
asthenia
Follow-up
No. of
further
treatments
0 1 1 1 0 0 0
Alive Yes Yes Yes Yes Yes No No
OS from
diagnosis of
metastatic
disease (mo)
65 96
©AlphaMed Press 2016
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Patient 7
The patient came to the treating institution for metastatic
breast cancer at the age of 69 years. Given the presence of
severe dilated cardiomyopathy, adjuvant therapy was not
performed. At the first relapse, the patient started hormonal
therapy, achieving good control of the disease. Eribulin was
used after three lines of therapy after the detection of four
brain metastases.The patient showed a complete response to
the brain injuries but died of a heart attack 1 month after the
initiation of eribulin.
Variable
Patient no.
8 9 10 11 12 13 14 15
Patient
characteristics
Age (yr) 69 68 54 55 64 66 55 61
Comorbidities None Hypertension Dyslipidemia None None COPD/
diabetes
TBC,
hypertension
Diabetes
Disease
characteristics
Age at
diagnosis
(yr)
64 63 51 46 54 52 47 57
Site R L L L R L L L
TNM pT2, pN1,
cM0
IV stage IV stage ypT4cN3aM1 pT2N3aM0 pT4 pN3
(11/16)
T4N1M1 T2N3aM0
Grade G3 G3 G2 G2 G2 G3 G2 2
HER2 31 21 Neg Neg Neg NE 11 Neg
ER (%) 92 90 100 80 95 80 90 Neg
PgR (%) 80 1 60 60 95 15 60 Neg
Ki-67 (%) 30 20 10 10 20 50 25 10
LVI No No Yes Yes Yes No No NE
Surgery Q M M M M M No M
Age at
metastasis
(yr)
67 63 51 46 60 62 47 58
Site Lung,
liver, bone
Lung,
lymph
nodes,
bone
Bone,
lung, pleura
Lymph
nodes,
lung, bone
Lymph
nodes, lung
Lung, lymph
nodes, skin
Lung,
bone
Bone
Previous
lines of
treatment
No. of
lines
2 5 3 8 5 2 4 3
Longest
PFS (mo)
5 14 6 NE NE 9 23 18
Best
response
PR SD SD NE NE PR PR SD
Eribulin
No. of
cycles
13 9 10 4 4 15 7 7
Dose
intensity
1.3 1.23 0.97 1.23 2.4 0.54 0.97 1.23
PFS 12 9 19 3 3 11 6 4
Reason for
interruption
No PD AE PD PD PD Toxicity PD
Best
response
CR brain PR PR SD SD PR PR SD
Toxicity G2 nausea,
asthenia,
neutropenia
G2 asthenia,
stypsis,
nausea
G3
neutropenia,
thrombocytopenia
None None G3
neutropenia
G2
neurotoxicity,
asthenia,
nausea
G2 asthenia,
anorexia
Follow-up
No. of
further
treatments
0 1 1 0 2 1 2 1
Alive Yes No No No Yes Yes No No
OS from
diagnosis of
metastatic
disease (mo)
57 37 67 80 56
Table 1. (continued)
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Patient 21
A 62-year-old man came to the treating institution after he
had undergone left radical mastectomy with ipsilateral
axillary lymph node dissection 5 years earlier, when he was
first diagnosed at the age of 57.The histological examination
revealed an infiltrating ductal breast carcinoma, grade 3,
pT1cN0M0; estrogen receptor, 0%; progesterone receptor,
0%; and negative HER2 status. The patient underwent
Variable
Patient no.
16 17 18 19 20 21 22 23
Patient
characteristics
Age (yr) 62 75 76 67 80 62 68 63
Comorbidities Stones,
diabetes,
hypertension
Hypertension,
AMI
None Diabetes Cardiomyopathy Hypertension Hypertension Hypertension,
carotid
stenosis
Disease
characteristics
Age at
diagnosis
(yr)
42 69 68 56 74 57 63 58
Site R R R L L L L R
TNM pT4N0M0 pT2 N1 pT1 pT1c N21 PT1c N0/
17 M0
pT1c N0M0 IV pT1c,
pN0, M0
Grade NE 3 G2 G2 G2 G3 G3 G3
HER2 Neg Neg Neg 21 Neg Neg 21 Neg
ER (%) 90 70 80 85 80 Neg 90 60
PgR (%) NE 40 80 75 15 Neg 1 55
Ki-67 (%) NE 20 18 40 50 30 20 25
LVI NE Neg NE NE No Yes No No
Surgery M M LD M M M1LD M1LD M1LD
Age at
metastasis
(yr)
45 72 72 57 77 61 63 59
Site Lung Bone,
liver
Lymph
node,
lung
Lymph
nodes
Lymph
nodes,
lung
Bone Lymph
nodes,
bone
Pleura
Previous
lines of
treatment
No. of
lines
11 3 2 5 2 2 3 5
Longest
PFS (mo)
33 13 4 21 8 17 14 15
Best
response
PR PR SD PR PR SD SD PR
Eribulin
No. of
cycles
6 12 3 3 5 7 9 4
Dose
intensity
1.23 1.23 1.23 1.23 1.76 1.23 1.23 1.23
PFS 6 14 2 NE 3 7 9 4
Reason for
interruption
PD No PD No PD PD PD PD
Best
response
SD SD SD PR SD SD PR SD
Toxicity None G2
neutropenia,
leukopenia,
neuropathy
G3 neutropenia,
G2 asthenia
None G1
neutropenia
None G2
asthenia,
G1 stypsis,
nausea
G1
paresthesia
Follow-up
No. of
further
treatments
1 1 0 0 2 0 1 1
Alive No Yes No Yes Yes No No Yes
OS from
diagnosis of
metastatic
disease (mo)
228 22 33 67
Abbreviations: AE, adverse event; AMI, acutemyocardial infarction; COPD, chronic obstructive pulmonary disease; CR, complete response; ER, estrogen
receptor; G, grade; L, left; LD, lymphadenectomy; LVI, lymphovascular invasion; M, mastectomy; NE, not evaluable; Neg, negative; OS, overall survival;
PgR, progesterone receptor; PD, progressivedisease; PFS, progression-free survival; PR, partial response; Pt.No., patient number;Q, quadrantectomy; R,
right; SD, stable disease; TBC, tuberculosis; TBD, to be determined.
Table 1. (continued)
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adjuvant chemotherapy with six cycles of 5-fluorouracil,
epirubicin, and cyclophosphamide. In February 2010, after
a suspected locoregional recurrence appeared on the
mastectomy scar, he underwent excision of the nodule.
Examination of the surgical specimen confirmed the previ-
ous histological and biological features (i.e., triple-negative
breast cancer). The patient underwent adjuvant radio-
therapy at the recurrence site and chemotherapy with
carboplatin area under the curve (AUC) 5, every 21 days
for six cycles. In February 2012, following the onset of
pain in the thoracic spine, restaging was undertaken with a
total body CT scan and bone scan, which showed bone
metastases. Therefore, the patient started treatment with
paclitaxel plus bevacizumab for six courses, followed by
bevacizumab maintenance until July 2013. He also received
zoledronic acid until August 2014.
Figure 1. Individual data on survival for all patients. (A): PFS shown from the initiation of eribulin treatment (not evaluated in patient 19
owing to the lack of progression at the time of analysis). (B):OS shown from the diagnosis of metastatic disease (for patients with a fatal
event only).
Abbreviations: PFS, progression-free survival; OS, overall survival.
www.TheOncologist.com ©AlphaMed Press 2016
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In September 2013, after clinical and instrumental bone
progression, the patient began treatment with vinorelbine,
5-fluorouracil, and folic acid day 1–3 every 3 weeks for eight
cycles until January 2014. Because further clinical and
instrumental disease progression at the bone was docu-
mented in February 2014, eribulin 1.23mg/m2ondays 1 and
8 every 3 weeks was started and was continued for seven
cycles, without any relevant toxicity, until September 2014
when the disease progressed. In November 2014, the
patient died of disease progression.
Patient 22
Patient 22 was a 68-year-old man, diagnosed in October
2009 with stage IV, luminal B-like left breast cancer, with
synchronous bone andmediastinal lymph nodemetastases.
He received first-line chemotherapy with epirubicin and
docetaxel, with disease progression after 3months. In order
to better understand the breast cancer subtype, he
underwent mastectomy with lymphadenectomy. The histo-
pathological analysis confirmed the diagnosis of invasive
ductal carcinoma, histological grade 3, positive for hormone
receptors. The breast surgical margins were free. After
surgery, the patient received first-line hormonal therapy
consisting of letrozole. He also underwent radiation therapy
to the symptomatic bone metastases.
Four months later, the disease had progressed. The
patient was treated with two more lines of chemotherapy
(anthracyclines and taxanes; carboplatin and gemcitabine).
Treatment with eribulin (1.23 mg/m2) was then instituted
and continued for nine cycles. The main toxicities were
asthenia, nausea, and stypsis (all grade 1). The patient’s
disease was stable for 9 months. He later died 67 months
after the diagnosis of metastatic disease because of a car
accident.
DISCUSSION
Although it usually presents with aggressive features, male
breast cancer remains a poorly characterized disease. The
current management of this condition has been determined
from the results of clinical trials of female breast cancer
patients. However, the existence of marked biological differ-
encesbetweenmaleand femalebreast cancerhasbeenshown
repeatedly [1, 2, 4].
At present, dedicated studies are needed to investigate the
biological and clinical characteristics ofmale breast cancerand to
determinethespecificmanagementforthisdisease[1].However,
owing to the rarity of male breast cancer, the conduction of
prospective studies has been difficult [4].Therefore, most pieces
of evidence for male breast cancer must be collected from
retrospective analyses, a type of study that can, however, be
informative in the oncological setting [16].
In the present retrospective, multicenter case series of
23 subjects, we have analyzed the clinical outcomes of
eribulin for patients with metastatic male breast cancer. To
our knowledge, this is the first report of eribulin use in this
population. Although the greatmajority of patients hadbeen
heavily pretreated, eribulinwas continued for amedian of six
cycles and was associated with a clinical response in almost
one half of the patients. No unexpected safety concernswere
reported, and approximately one third of evaluated subjects
did notexperience any relevant adverse eventduring eribulin
treatment.
CONCLUSION
Althoughhamperedbyall the limitationsofanyretrospectivecase
series and the lack of specific analyses on survival owing to the
heterogeneity of patients, we believe that the present analysis
addsto thecurrentknowledgeof themanagementofmalebreast
cancer. Our results suggest for the first time the potential use of
eribulin in the therapy of this disease. While waiting for other
studies to either confirm or discard these preliminary findings,
eribulin might be worth consideration in the treatment of
pretreated patients with male breast cancer.
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Pisconti, Mirco Pistelli, Anna Rizzi, Nello Salesi, Alessio Schirone, Giovanni
Scognamiglio, Maria Tedeschi, Patrizia Zucchinelli
Final approval of manuscript: Francesco Giotta, Luigi Acito, Giampiero
Candeloro, Gennaro Gadaleta-Caldarola, Guido Giordano, Rossana
Gueli, Antonio Lugini, Valentina Magri, Marta Mandarà, Giovanna
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For Further Reading:
Giovanna Masci, Michele Caruso, Francesco Caruso et al. Clinicopathological and Immunohistochemical Characteristics in
Male Breast Cancer: A Retrospective Case Series. The Oncologist 2015;20:586–592.
Implications for Practice:
There is little evidence that prognostic featuresestablished in femalebreast cancer, suchas gradingandKi-67 labeling index,
could beapplied tomale breast canceraswell.This study found that grade3was associatedwith shorteroverall survival and
a trend for Ki-67>20%; this could help in choosing thebest treatmentoption in the adjuvant setting.Manyquestions remain
regarding the impact of HER-2 positivity on survival and treatmentwith adjuvant anti-HER-2 therapy. Regardingmetastatic
male breast cancer, the results suggest that common regimens of chemo-, endocrine and immunotherapy used in female
breast cancerare safe andeffective formen.Malebreast cancerpatients showahigher incidenceof secondprimary tumors,
especially prostate and colon cancers and should therefore be carefully monitored.
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